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A B S T R A C T
Background
Tetanus is a severe disease that can be prevented by vaccination. In developing countries vaccination coverage is not always high. Cases
still occur also in developed countries, particularly in elderly people owing to their reduced immuno protection. There are about 1
million tetanus cases per year globally. In animal studies, vitamin C has protected against various infections and bacterial toxins. In a
study with rats, vitamin C protected against the purified tetanus toxin.
Objectives
To assess the prophylactic and therapeutic effect of vitamin C on tetanus.
Search methods
In May 2013 we searched the Cochrane Wounds Group Specialised Register; The Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library); Ovid MEDLINE; Ovid MEDLINE (In-Process & Other Non-Indexed Citations ); and Ovid
EMBASE for this third update.
Selection criteria
Controlled trials of vitamin C as a prevention or treatment for tetanus, whether or not these were placebo controlled, in any language,
published or unpublished. Two review authors independently made inclusion decisions.
Data collection and analysis
Both review authors independently extracted data from trial reports and assessed methodological quality. Since one of the cells in a
2 × 2 table had no events, we calculated the odds ratio (OR) and its 95% confidence interval (CI) for case fatality rate by using the
Peto-method. Another of the 2 × 2 tables had no empty cells and the inverse-variance method was used to calculate its risk ratio (RR)
estimate and 95% CI. We also used the Fisher’s exact test to calculate the exact 95% CI for the OR of the 2 × 2 table with the empty
cell.
Main results
One single trial was eligible for inclusion. This non-randomised, unblinded, controlled trial undertaken in Bangladesh involved 117
tetanus patients. Vitamin C at a dosage of 1 g/day was administered intravenously alongside conventional treatment. At recruitment,
the participants were stratified into two age groups and the results were reported by age. There was a significant difference in the
vitamin C effect between the two age groups (P = 0.01). In the tetanus patients aged 1 to 12 years (n = 62), vitamin C treatment was
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associated with a 100% reduction in case fatality rate (95% CI from -100% to -94%). In patients aged 13 to 30 years (n = 55), vitamin
C treatment was associated with a 45% reduction in case fatality rate (95% CI from -69% to -5%).
Authors’ conclusions
A single, non-randomised, poorly reported trial of vitamin C as a treatment for tetanus suggests a considerable reduction in mortality.
However, concerns about trial quality mean that this result must be interpreted with caution and vitamin C cannot be recommended
as a treatment for tetanus on the basis of this evidence. New trials should be carried out to examine the effect of vitamin C on tetanus
treatment.
P L A I N L A N G U A G E S U M M A R Y
Vitamin C for preventing and treating tetanus
Tetanus is a disease caused by tetanus toxin, which is produced by the bacterium Clostridium tetani. This bacterium typically infects
penetrating wounds contaminated by foreign material such as soil. In developing countries, poor hygiene after childbirth may cause
tetanus in newborn babies. Even though vaccination has dramatically decreased the burden of tetanus, there are still about 1 million
tetanus cases per year globally. We found one controlled trial that examined whether one gram per day of intravenous vitamin C would
help in the treatment of tetanus patients. Vitamin C was used alongside standard treatments for tetanus. Intravenous vitamin C reduced
the mortality of children aged between 1 and 12 with tetanus by 100% and that of 13 to 30 year old patients by 45%. The trial was not
properly conducted and caution is required in the interpretation of the findings. Vitamin C cannot be recommended as a treatment
for tetanus on the basis of this single study. Further investigation of the role of vitamin C in tetanus treatment is warranted.
B A C K G R O U N D
Description of the condition
’Tetanus’ denotes a disease caused by tetanus toxin (tetanospas-
min), a protein that is produced by the anaerobic bacterium
Clostridium tetani. Although the pathological definition of tetanus
is based on the specified bacterium and its toxin, the diagnosis
is made clinically. The clinical picture is dominated by muscle
spasms and rigidity. Often the first sign is rigidity of the jaw mus-
cles, followed by stiffness of the neck, difficulty in swallowing, and
rigidity of the abdominal muscles. Other symptoms include ele-
vated temperature, raised blood pressure, and an episodically rapid
heart rate. Tetanus may lead to complications such as fractures of
the spine or long bones because of contractions and convulsions,
and to pulmonary embolism, bed sores and nosocomial infections
due to prolonged hospitalisation. The current treatment of tetanus
consists, for example, of surgical debridement of the wound and
antibiotic therapy (metronidazole) to remove the source of in-
fection, tetanus immune globulin to neutralize circulating toxin,
and benzodiazepine for sedation and muscle relaxation (Thwaites
2006; Gibson 2009; Reddy 2010; Afshar 2011; Ataro 2011; CDC
2013; WHO 2013).
Tetanus is typically caused by anaerobic bacterial growth in a con-
taminated penetrating wound. Vaccination against tetanus has
dramatically reduced the incidence of the disease in developed
countries, but infrequent cases occur, particularly in elderly peo-
ple owing to reduced immuno protection (Gergen 1995; Yuan
1997). Nevertheless, about 1 million cases of tetanus are reported
worldwide annually (Afshar 2011). In developing countries case
fatality rate is about 50%, whereas in developed countries with
intensive care units (ICU) the case fatality rate is less than 20%
(Afshar 2011).
In developing countries, neonatal tetanus causes over 100,000 in-
fant deaths per year, due largely to poor umbilical hygiene after
childbirth. According to the World Health Organization (WHO),
Somalia had the highest rate in 1999, with 16.5 neonatal tetanus
deaths per 1000 live births (WHO 2000). It is noteworthy that
vitamin C deficiency has also been particularly common in So-
malia (WHO 1999). Vaccination of mothers would prevent the
majority of these cases and the WHO has campaigned to increase
the coverage of vaccination in developing countries (WHO 2000;
Demicheli 2013; Khan 2013; WHO 2013).
Although the molecular mechanisms of the tetanus toxin in the
initiation of pathogenesis are well known, the later stages of the
pathological cascade are inadequately understood. There is evi-
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dence indicating that disturbances in autonomic control with sym-
pathetic overactivity (e.g. elevated blood pressure, rapid heart rate)
could play a crucial role in the pathophysiology of severe tetanus
cases (Daher 1997; Wasay 2005; CDC 2013). The possible role of
catecholamines (stress hormones) in tetanus was supported by data
reported by Thwaites 2006a. The concentrations of epinephrine
and norepinephrine were much higher in tetanus patients than in
other critically ill patients and, amongst the tetanus patients, the
concentrations were higher in those who had more severe forms
of tetanus.
Description of the intervention
Vitamin C was identified in the early 1900s in the search for the
substance, the deficiency of which causes scurvy (Carpenter 1986).
After the identification there was interest in its effects on diseases
unrelated to scurvy, but the role of vitamin C on other diseases is
still unsettled.
According to systematic reviews, over two dozen controlled trials
have shown that vitamin C shortens the duration of colds (Hemilä
2013), five trials found that vitamin C halved the incidence of
colds in participants who endured short-term heavy acute physical
stress (Hemilä 2013), three trials found that vitamin C alleviated
exercise-induced bronchoconstriction (Hemilä 2013a), two trials
reported therapeutic benefit for pneumonia patients and three
reported prophylactic benefit against pneumonia under special
circumstances (Hemilä 2013b). In randomised trials with critically
ill patients, vitamin C alone (Tanaka 2000; Papoulidis 2011;
Bjorndahl 2012) or in the combination with vitamin E (Nathens
2002) significantly decreased the length of mechanical ventilation
or the length of ICU stay or both. Although such findings indicate
that the effects of vitamin C are not limited to preventing scurvy,
their practical significance is not yet clear.
Two large trials with US male physicians and female health profes-
sionals found no benefits of 0.5 g/day of vitamin C (Cook 2007;
Sesso 2008), but these trials are not discordant with the possibil-
ity that vitamin C administration may influence health on special
conditions, such as when a person endures heavy physical activity
or suffers from an infection.
An early case report claimed benefit of vitamin C against tetanus
in an unvaccinated six-year-old boy in the USA, but the specific
role of vitamin C cannot be inferred from the report (Klenner
1954).
Usually vitamin C is administered as tablets, but it can also be ad-
ministered intravenously. A pharmacokinetic study compared oral
and intravenous administration and found substantially higher
plasma levels when vitamin C was administered by intravenous
route compared with oral administration (Padayatty 2004). The
highest dose used in the pharmacokinetic study, 100 g of vita-
min C intravenously given over a few hours, increased the plasma
concentration peak to 15,000 µmol/L, which is over 100 times
the plateau level reached by high dose oral administration (Levine
1996; Padayatty 2004).
Vitamin C is safe in high doses. A dose of approximately 10 mg/
day prevents scurvy but, according to the US nutritional recom-
mendations, the ’tolerable upper intake level’ is 2 g/day for adults
(IOM 2000). The basis for this upper limit is the appearance of
diarrhoea, which is, however, a trivial adverse effect that disappears
quickly with a reduction in intake. Several other reviewers have
also concluded that vitamin C is safe in doses ranging to several
grams per day (Hathcock 2005; Hemilä 2006).
How the intervention might work
As described above, elevated levels of catecholamines (stress hor-
mones) may play a role in the pathophysiology of tetanus. Vita-
min C might influence tetanus, for example, through its effects
on catecholamine metabolism. First, vitamin C is involved in the
synthesis of norepinephrine and the adrenal glands have the high-
est concentration of this vitamin in the body (Diliberto 1991;
Rice 2000; Patak 2004; Kato 2006). Second, in an animal model
vitamin C with vitamin E and β-carotene protected against the
cardiotoxic effects of high levels of norepinephrine (Qin 2001).
Third, various infections and purified bacterial toxins deplete vi-
tamin C from the adrenal glands and other tissues (Hemilä 2006).
Thus, vitamin C might influence conditions where catecholamine
metabolism is changed.
A few laboratory studies have shown that vitamin C improved the
functions of phagocytes and the proliferation of T-lymphocytes,
indicating that it has roles in the immune system (Hemilä 2006;
Webb 2007). In dozens of animal studies, vitamin C increased
resistance against diverse infections and purified bacterial toxins
(Hemilä 2006). In particular, Dey 1966 reported that five rats
administered twice the minimal lethal dose of tetanus toxin all
died, whereas 25 rats administered vitamin C either before or
after the toxin all lived (Hemilä 2006). Vitamin C also reduced
mortality in mice caused by toxins of several Clostridium species
(Büller Souto 1939 [see the data extracted in: Clemetson 2002;
Hemilä 2006]).
Chakrabarti 1955 reported that tetanus patients had lower plasma
vitamin C levels than healthy people, and tetanus patients who
died had lower levels than those who survived. Furthermore,
tetanus patients had elevated levels of dehydroascorbate, which
is the oxidized form of vitamin C. Such changes in vitamin C
metabolism provide a further rationale to test vitamin C for tetanus
patients.
Although vitamin C influences the immune system, it may be im-
portant only in particular conditions. For example, it is possible
that variation in dietary vitamin C intake is not crucial in the or-
dinary western population because of their relatively high dietary
intake levels, yet vitamin C might be a limiting factor in popu-
lations with low intakes. In the extreme, the prevalence of scurvy
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(vitamin C deficiency) was reported to be up to 44% in refugee
camps in Somalia (WHO 1999).
Why it is important to do this review
Tetanus is a severe disease afflicting about 1 million people an-
nually and vitamin C is a safe and inexpensive essential nutrient.
The possibility that vitamin C may have an action on tetanus is
therefore worthy of systematic consideration.
Links to the publications cited in this Background section,
for which full text versions are available, can be found at:
www.mv.helsinki.fi/home/hemila/CT
O B J E C T I V E S
To determine the effects of vitamin C supplementation for:
(1) preventing the development of tetanus in vaccinated and un-
vaccinated individuals;
(2) treating patients with a diagnosis of tetanus.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Controlled clinical trials, both randomised and non-randomised.
The review includes studies with and without placebo control
since, firstly, it is unlikely that being aware of taking or not tak-
ing vitamin C would influence such a severe disease as tetanus;
and secondly, a recent meta-analysis of trials comparing a placebo
group with a no-treatment group found no evidence of a substan-
tial placebo effect on binary outcomes, although placebo did have
an effect on pain measured as a continuous outcome (Hrobjartsson
2010).
Types of participants
We included studies involving people of any age and sex, either
vaccinated or unvaccinated (prevention) or who had a diagnosed
condition of tetanus (treatment). In this review we include both
neonatal tetanus and tetanus cases occurring after the neonatal
period.
Types of interventions
Studies in which treatment with vitamin C was the only systematic
difference between the treatment arms were eligible for inclusion.
We included studies comparing outcomes after the administration
of vitamin C (ascorbic acid or its salts or other derivatives; orally
or intravenously) with the administration of no or a lower dose of
vitamin C. We did not apply restrictions on the dosage and fre-
quency of administration of vitamin C, and we considered treat-
ment trials using a single dose and trials in which vitamin C was
administered with other treatments, provided co-interventions did
not differ between the treatment arms. We regarded ’prevention
trials’ as those in which regular vitamin C was administered to
people who did not have tetanus and ’treatment trials’ as those in
which vitamin C was administered after the diagnosis of tetanus.
Types of outcome measures




1. Incidence of tetanus.
Treatment trials:
1. Mortality;




2. Duration of hospital stay;
3. Severity of symptoms and complications.
Treatment trials:
1. Severity and occurrence of complications such as fractures
and nosocomial infections.
Search methods for identification of studies
Electronic searches
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For an outline of the search methods used in second update of this
review see Appendix 1.
We searched the following databases in May 2013 for this third
update:
• The Cochrane Wounds Group Specialised Register
(searched 22 May 2013);
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2013, Issue 4);
• Ovid MEDLINE (1946 to May Week 2 2013);
• Ovid MEDLINE (In-Process & Other Non-Indexed
Citations, May 16, 2013);
• Ovid EMBASE (2011 to 2013 Week 19);
The following strategy was used to search The Cochrane Central
Register of Controlled Trials (CENTRAL):
#1 MeSH descriptor Tetanus explode all trees
#2 tetanus
#3 (#1 OR #2)
#4 MeSH descriptor Ascorbic Acid explode all trees
#5 ascorb* or “vitamin C”
#6 (#4 OR #5)
#7 (#3 AND #6)
The search strategies for Ovid MEDLINE and Ovid EMBASE
can be found in Appendix 2 and Appendix 3 respectively. No
methodological filters were used. No date or language restrictions
were applied.
Searching other resources
Previously, Briggs 1984 carried out extensive literature searches
and published a bibliography containing over 400 references to
papers related to vitamin C and infections, which we checked,
as well as the reference lists of two books on potential clinical
effects of vitamin C (Stone 1972; Levy 2002). We also searched the
reference lists of all other pertinent reviews and of the potentially
eligible studies identified in our search.
Data collection and analysis
Selection of studies
The first review author searched the literature and both review
authors independently assessed the titles and abstracts to identify
potentially relevant articles. We obtained full versions of all po-
tentially eligible articles, which we scrutinised independently.
Data extraction and management
Both review authors independently extracted pertinent data from
the articles selected. We recorded the following quality features
of the trials on data extraction forms as ’yes’, ’no’, ’unclear’: ran-
domised allocation, allocation concealment, blinding of partici-
pants, blinding of investigator, blinding of outcome assessor, blind
data analysis and intention-to-treat analysis. We also recorded
baseline measurements and percentage dropout during follow up.
Assessment of risk of bias in included studies
We did not calculate any quality scores because “the use of scales
for assessing quality or risk of bias is explicitly discouraged in
Cochrane reviews” (Higgins 2011). We describe the weaknesses
and strengths of the included trial explicitly in the ’Risk of bias in
included studies’ section.
Measures of treatment effect
We entered the case fatality rate data of the identified Jahan 1984
study to the RevMan 2012 computer program and calculated
the odds ratio (OR) as an approximation of the risk ratio (RR)
(Rothman 1998), presenting the results with the 95% confidence
intervals (CI). Because one cell in the 2 × 2 table was empty in the
comparison of children we used the Peto-method for calculating
the OR. We also used the Fisher’s exact test of the R-Project 2013
package to calculate the exact 95% CI for the OR and the Fisher’s
exact test P-value for the comparison. We used two-tailed P values
in this review.
Unit of analysis issues
The patients in the Jahan 1984 trial were divided into two wards
by vitamin C administration. Although this may cause bias in
treatment and observations, it does not affect the unit of analysis
(the individual patient), because tetanus is not a contagious disease.
Assessment of heterogeneity
We assessed the heterogeneity of comparisons by using I2 (Higgins
2003). This examines the percentage of total variation across stud-
ies that is due to heterogeneity rather than chance. A value of I2
greater than about 70% indicates a high level of heterogeneity. We
also used the χ2 test to calculate the probability that the observed
heterogeneity was caused by chance.
Data synthesis
We did not pool the age groups of the Jahan 1984 trial, because
there was a high level of heterogeneity.
R E S U L T S
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Description of studies
No new eligible trials were identified in the searches carried out for
the 2013 update of this review. From the original search we found
one eligible controlled trial that provided data pertinent to vitamin
C in the treatment of tetanus patients (Jahan 1984), but we found
no trials reporting on the prevention of tetanus with vitamin C.
The main features of the Jahan trial are briefly summarised in the
table ’Characteristics of included studies’, but described in detail
in the following section because its weaknesses and strengths are
crucial when considering the validity of it’s findings. The Jahan
1984 trial was carried out in Bangladesh in the early 1980s. A total
of 117 tetanus patients were admitted to the Infectious Disease
Hospital in Dhaka and divided into two age groups at recruitment.
There were 62 children in the age group 1 to 12 years, and 55
children and adults in the age group 13 to 30 years. The Jahan
report is available at www.mv.helsinki.fi/home/hemila/CT
Risk of bias in included studies
Jahan 1984 did not describe the allocation method, but the vi-
tamin C and control arms were of the same size: 31 vitamin C
patients compared with 31 control participants in the younger age
band; and 27 (vitamin C) compared with 28 (control) in the older
participants. Allocation concealment could not be judged from
the report. Patients allocated to the vitamin C group received 1 g/
day intravenously “in addition to conventional antitetanus ther-
apy which included antitetanus serum, sedatives, antibiotics and
muscle relaxant etc.” (p 25). Participants allocated to the control
arm received conventional antitetanus therapy but the adminis-
tration of placebo is not mentioned. No baseline data, except for
the age ranges, are presented for the two trial arms. There is no
description of how tetanus was diagnosed. The authors present
results for 117 patients in a table indicating that all recruited pa-
tients were included in the analysis. The trialists did not state the
duration of intervention or their duration of follow-up, but stated
that “patients succumbed to tetanus even three to four weeks after
admission” (p 27).
Thus, the Jahan 1984 trial had two age groups with treatment
and control arms of similar size and administration of vitamin C
was the only systematic difference between them. However, the
methodological description in the Jahan report is minimal. The
role of the methodological shortcomings in the interpretation of
the study results are considered in the ’Discussion’ section.
We were able to contact the first author of the Jahan 1984 trial.
To our query about the methods of the 1984 trial, we received this
reply: “we selected two wards side by side. Patients of one ward
were under treatment with vitamin C in addition to conventional
treatments. In another ward patients were enrolled as a control
group and got only the conventional treatment (without vitamin
C). Age groups and the number of patients we tried to match
as far as possible. Because we had to take the patients who were
inpatients in the hospital we did not use a placebo. We were not
able to hide the allocations from the physicians at that stage. Follow
up of the patients was until they were discharged as fit persons or
died. Diagnosis of the disease was done by a physician specialised




We did not identify any trials describing the effects of vitamin C
as a prevention for tetanus.
Treating tetanus
Effect on case fatality rate
We identified one controlled trial that examined the effects of 1
g/day vitamin C given intravenously for tetanus patients (Jahan
1984). At recruitment, the tetanus patients were stratified into two
age groups and the results were reported by the age groups. Since
one of the 2 × 2 table cells was empty among the younger patients,
in Figure 1 we present the effect estimates for OR by using the
Peto-method.
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Figure 1. Effect of vitamin C on tetanus case fatality rate by age groups in Jahan 1984
Age group 1 to 12 years: vitamin C significantly reduced the case
fatality rate (0%; 0/31) compared with the control group (74%;
23/31). The Peto-OR for the difference between the vitamin C
and control groups was 0.04 (95% CI from 0.02 to 0.12); this
is shown as subgroup 1 in Figure 1. Because of the empty cell,
we also calculated the exact 95% CI for the OR for the young
tetanus patients. The exact OR of death was 0.0 (95% CI from 0.0
to 0.06) which is thus slightly narrower than the 95% CI of the
Peto-OR (Figure 1). The Fisher’s exact test gives P = 10−9 for the
comparison of vitamin C and control arms of the young patients.
Age group 13 to 30 years: vitamin C significantly reduced the case
fatality rate (37%; 10/27) compared with the control group (68%;
19/28). The Peto-OR for the difference between the groups was
0.30 (95% CI from 0.10 to 0.85); this is shown as subgroup 2
in Figure 1. The inverse variance RR estimate given by RevMan
is RR = 0.55 (95% CI: 0.31 to 0.95; P = 0.03), which is a more
practical measure of vitamin C effect than the OR.
Heterogeneity between the subgroups
We found strong evidence of heterogeneity in the effect of vitamin
C between the young and old patients with P = 0.01 for the test
of heterogeneity over the two age groups. The I2 value of 85%
indicates a high level of heterogeneity. The authors of the Jahan
1984 trial reported the results of the age groups separately. We did
not calculate a pooled vitamin C effect because of the high level
of heterogeneity.
Sensitivity analysis based on the rejection of trials with lower
methodological quality was not possible because we identified only
one trial.
D I S C U S S I O N
Quality of the evidence
We identified one trial that examined the therapeutic effect of vi-
tamin C on the mortality of people with tetanus (Jahan 1984). In
this 2013 update, no new trials were identified. The Jahan 1984
trial reported a highly significant benefit associated with intra-
venous vitamin C on the case fatality rate of tetanus patients. The
methods used in the Jahan trial were, however, unsatisfactory and
superficially described. Here we will consider whether potential
biases could explain the differences reported in the case fatality
rate between the vitamin C and control arms.
Jahan 1984 did not state an explicit case definition for tetanus.
Although this is a shortcoming in the report, it does not seem
reasonable to assume that tetanus was improperly diagnosed in an
infectious diseases hospital in a country that had a high incidence
of this disease (currently the incidence is lower). Furthermore, the
trial author described in a personal letter that the diagnosis was by
a “physician specialised in infectious diseases”.
Selection bias operates when there are systematic differences be-
tween comparison groups at baseline. Adequate randomisation
with allocation concealment guards against it. No data were pre-
sented by Jahan 1984 to allow us to judge whether the allocation
process resulted in balanced allocation between treatment groups
for prognostic factors. This trial was not randomised and there
is a risk of selection bias (the ward a patient was allocated to de-
termined whether they received vitamin C, and there might have
been a systematic difference in the allocation to the wards). How-
ever, it is highly unlikely that potential baseline differences could
lead to such great difference in mortality between the study arms
as reported for the younger patients.
Performance bias operates when there are systematic differences
in the care provided apart from the intervention being evalu-
ated. Jahan 1984 stated that both vitamin C and control arms
received “conventional antitetanus therapy which included antite-
tanus serum, sedatives, antibiotics and muscle relaxant etc.”, so
the administration of vitamin C was the only systematic differ-
ence between the trial arms. However, the vitamin C and control
patients were treated in different wards, which is unsatisfactory
because aspects of treatment could be somewhat different between
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the two wards. Placebo was not used in Jahan 1984, however, a
recent meta-analysis showed that, in trials examining various top-
ics, placebo arms did not differ from no-treatment arms if the
outcome was binary; e.g. mortality (Hrobjartsson 2010). Thus,
the care providers may have been aware of which arm the patients
had been enrolled into, but it is highly unlikely that such knowl-
edge would have altered treatment to such an extent that it could
explain the difference in mortality between the study arms as re-
ported for the younger patients in Jahan 1984.
Attrition bias operates when there are large numbers of people
who withdraw from the study or when the rates of withdrawal
are different between treatment arms. Attrition bias is unlikely in
Jahan 1984, since all patients allocated were followed up and anal-
ysed. Furthermore, in a personal letter, the trial author confirmed
that all patients were followed up “until they were discharged as
fit persons or died”.
Detection bias operates when there are systematic differences in
the ways outcomes were assessed between treatment groups and is
more likely to occur when there is no blinded outcome assessment
and when the outcome is subjective. It is unlikely, however, that
detection bias is operating in Jahan 1984 since the outcome was
mortality which is not a subjective outcome. There is minimal
possibility of bias in detecting mortality in a hospital.
Consequently, although the methods of the Jahan 1984 trial are
poorly described and the trial was poorly conducted, the biases
discussed above cannot explain the reported findings. There seems
to be no basis to assume attrition bias or detection bias in the
trial. Possibly there has been selection bias and performance bias
to some degree, but this cannot explain the reported difference in
outcomes among the younger participants. Glasziou 2007 argued
that rate ratios beyond 10 are highly likely to reflect real treatment
effects, even if confounding factors may contribute to the size of the
observed effect. In the younger patients of the Jahan trial, the entire
95% CI and not just the point estimate is beyond the ratio of 10.
In the older patients of the Jahan trial, the upper limit of the 95%
CI is close to the control group level, and therefore the results are
not robust to the possibility of selection and performance biases.
Nevertheless, the findings in the older patients are consistent with
the findings in the younger patients.
Finally, the existence of a single positive study might be explained
by publication bias, meaning that researchers tend to report stud-
ies with ’positive’ results but not those with ’negative’ results. With
this reasoning, it is possible that Jahan 1984 was published just
because vitamin C appeared beneficial (but simply by chance),
whereas several trials might remain unpublished because of their
negative results. Publication bias may explain findings that are
close to statistical significance, but it is not a reasonable explana-
tion for highly statistically significant findings such as those of the
younger patients in the Jahan 1984 trial. Furthermore, it would
seem incomprehensible that publication bias would generate the
highly significant heterogeneity over the age groups. Therefore we
do not consider that publication bias is relevant in this case.
Applicability of the evidence
The Jahan 1984 trial is methodologically unsatisfactory and cau-
tion is required in the interpretation of the results. There are no
other trials with humans giving independent direct support to the
findings. Nevertheless, in western countries tetanus patients are
treated in ICUs, and four randomised trials with critically ill pa-
tients found that vitamin C alone or with vitamin E reduced the
duration of mechanical ventilation or the length of ICU stay or
both (Tanaka 2000; Nathens 2002; Papoulidis 2011; Bjorndahl
2012).
In the Jahan 1984 trial, vitamin C was used over and above treat-
ments that are still used for treating tetanus patients. In this re-
spect, the trial is not outdated.
When considering extrapolation of the findings of vitamin C tri-
als, one issue of particular importance is the level of dietary vita-
min C intake. A different outcome between the vitamin C and
control arms may result from a particularly low dietary intake in
the control arm (’marginal vitamin C deficiency’) or from the high
dose supplementation in the vitamin C arm. In the former case, a
small dosage of supplement may produce a similar effect, whereas
in the latter case the high dose is necessary. As reference levels:
scurvy may be caused by vitamin C intake of less than 10 mg/day,
whereas the mean vitamin C intake, for example, in the USA is
about 100 mg/day (IOM 2000).
If the biological basis for the results in Jahan 1984 was the treat-
ment of marginal deficiency, this would not provide an explana-
tion for the significant heterogeneity between the age groups, as
the dose is so high that it would cure marginal deficiency in both
age groups. Thus, it is possible that the high dose, 1 g/day, was
essential for the results. The benefit of vitamin C was significantly
greater for the younger patients (1 to 12 years), who weigh on
average less than the older patients (13 to 30 years). Thus the
heterogeneity might have resulted from dose dependency because
the dose per weight was higher in the younger patients. However,
there are other differences between the younger and older patients,
and some of them might explain the heterogeneity as well.
In the Jahan 1984 trial, vitamin C was administered intravenously
which increases plasma level substantially more than oral admin-
istration (Padayatty 2004). Therefore, the same dose of vitamin C
as tablets might not have similar effects.
Safety of vitamin C
In the Jahan 1984 report, no adverse effects related to the intra-
venous 1 g/day vitamin C administration were mentioned.
Two large-scale trials with 8171 female health professionals and
14,641 male physicians found no adverse effects of 0.5 g/day of
vitamin C when administered for 8 to 9 years indicating long term
safety of such a dosage level (Cook 2007; Sesso 2008).
There is also evidence that high dose vitamin C is usually safe
when administered intravenously. A matched case control study
of cancer patients found that 10 g/day vitamin C by intravenous
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infusion for 10 days and orally thereafter was associated with a
longer survival time which indicates the absence of harmful ef-
fects with such a dosage (Cameron 1976). Large doses of vita-
min C have been administered intravenously for numerous pa-
tients without adverse effects (Padayatty 2006; Padayatty 2010).
In a pharmacokinetic study, no adverse effects were reported with
the administration of up to 100 g of vitamin C intravenously to
healthy people (Padayatty 2004). A case report described the use
of intravenous vitamin C doses at levels up to 28 g/day for a six-
year-old boy with tetanus (Klenner 1954).
Cathcart 1981 stated that patients with severe infections can take
over 30 g/day of vitamin C orally without suffering from diar-
rhoea, whereas healthy people can take only 4 to 10 g/day. This
difference in tolerable doses may be caused by the changes in vita-
min C metabolism because of severe infections (Chakrabarti 1955;
Hemilä 2006). Thus, it is possible that the range of safe doses
extends to higher levels in people who have severe infections com-
pared with healthy people.
There are few reports of severe harm caused by high-dose vitamin
C administration. Furthermore, the death of a 68-year-old African
American man was not attributed to the intravenous injection
of 80 grams of vitamin C on two consecutive days per se, but
to his coincident glucose-6-phosphate dehydrogenase deficiency
(G6PD) (Campbell 1975). Such unfortunate events do not have
public health importance, although they discourage use of large
vitamin C doses to G6PD patients.
Consequently, there seems to be no concern about the safety of
the intravenous dosage level, 1 g/day, used in Jahan 1984.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
A single poor quality and poorly reported controlled trial found
that 1 g/day intravenous vitamin C significantly reduced tetanus
case fatality rate. Potential biases do not easily explain the differ-
ences between the vitamin C and control groups, but the short-
comings of this trial mean that routine vitamin C use cannot be
recommended on the basis of this trial alone. There were no eval-
uations of vitamin C as a prevention for tetanus.
Implications for research
Treatment trials: the particularly dramatic effect reported for chil-
dren in Jahan 1984 implies that more research is needed into the
effect of vitamin C on mortality of tetanus patients. Vitamin C
should be studied as an addition to conventional therapy.
Prevention trials: because of vaccination, tetanus is nearly non-ex-
istent in children and middle-aged people in the developed world.
Although vaccination should be a priority in developing countries,
the prophylactic effects of vitamin C supplementation might be
investigated in populations with a high incidence of tetanus and
low dietary vitamin C intake levels, which coexist, for example, in
Somalia (WHO 1999; WHO 2000).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Jahan 1984
Methods Non randomised; allocation method not described.
Vitamin C and control participants treated in separate wards.
No placebo; no blinding.
Duration up to 4 weeks.
Participants 117 tetanus patients admitted to the Infectious Disease Hospital, Dhaka, Bangladesh.
Age group 1 to 12 years: 31 vitamin C, 31 control.
Age group 13 to 30 years: 27 vitamin C, 28 control.
Interventions Vitamin C intravenously 1 g/day vs. no vitamin C. Both groups received standard treat-
ment
Outcomes Case fatality rate.
Notes Poorly described trial (see Risk of bias in included studies).
Additional information was received from the first author, Professor Jahan
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “we selected two wards side by side. Patients
of one ward were under treatment with vi-
tamin C in addition to conventional treat-
ments. In another ward patients were en-
rolled as a control group and got only the
conventional treatment (without vitamin
C)”. Personal communication with trial au-
thor. No randomisation took place
Allocation concealment (selection bias) High risk Allocation method not described, see above
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Patients in one ward were administered
vitamin C and patients in another ward
served as control. This was known to per-
sonnel but it is not clear whether it was
known to the patients
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Mortality in a hospital is not biased by sub-
jective observations
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Jahan 1984 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop outs according to the report
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D A T A A N D A N A L Y S E S
Comparison 1. Vitamin C vs control




participants Statistical method Effect size
1 Case fatality rate 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
1.1 aged 1 to 12 years 1 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 aged 13 to 30 years 1 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 Vitamin C vs control, Outcome 1 Case fatality rate.
Review: Vitamin C for preventing and treating tetanus
Comparison: 1 Vitamin C vs control
Outcome: 1 Case fatality rate





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 aged 1 to 12 years
Jahan 1984 0/31 23/31 0.04 [ 0.02, 0.12 ]
2 aged 13 to 30 years
Jahan 1984 10/27 19/28 0.30 [ 0.10, 0.85 ]
0.05 0.2 1 5 20
Favours vitamin C Favours control
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A P P E N D I C E S
Appendix 1. Search methods for the second review update (2011)
Electronic searches
For an outline of the search methods used in first update of this review see Appendix 1.
For this second update the following databases and dates are covered:
• Cochrane Wounds Group Specialised Register (searched 4 August 2011);
• Cochrane Infectious Diseases Group Specialised Register (searched 24 August 2011);
• The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2011, Issue 3);
• Ovid MEDLINE (1950 to August Week 2 2011);
• Ovid MEDLINE (In-Process & Other Non-Indexed Citations August 18, 2011);
• Ovid EMBASE (2009 to 2010 Week 50)
The following strategy was used to search The Cochrane Central Register of Controlled Trials (CENTRAL):
#1 MeSH descriptor Tetanus explode all trees
#2 tetanus
#3 (#1 OR #2)
#4 MeSH descriptor Ascorbic Acid explode all trees
#5 ascorb* or “vitamin C”
#6 (#4 OR #5)
#7 (#3 AND #6)
The search strategies for Ovid MEDLINE and Ovid EMBASE can be found in Appendix 2 and Appendix 3 respectively. No method-
ological filters were used. No date or language restrictions were applied.
Searching other resources
Previously, Briggs 1984 carried out extensive literature searches and published a bibliography containing over 400 references to papers
related to vitamin C and infections, which we checked. We also searched the reference lists of all other pertinent reviews and of the
potentially eligible studies identified in our search.
Appendix 2. Ovid MEDLINE search strategy
1 exp Tetanus/
2 exp Tetanus Toxin/
3 exp Tetanus Toxoid/
4 tetanus.mp.
5 or/1-4
6 exp Ascorbic Acid/
7 ascorb$.mp.
8 (vitamin$ adj5 C).mp.
9 or/6-8
10 5 and 9
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Appendix 3. Ovid EMBASE search strategy
1 exp Tetanus/
2 exp Tetanus Toxin/
3 exp Tetanus Toxoid/
4 tetanus.mp.
5 or/1-4
6 exp Ascorbic Acid/
7 ascorb$.mp.
8 (vitamin$ adj5 C).mp.
9 or/6-8
10 5 and 9
W H A T ’ S N E W
Last assessed as up-to-date: 16 June 2013.
Date Event Description
5 September 2013 New citation required but conclusions have not
changed
Third update, new search, no new trials identified. No
change to conclusions
5 September 2013 New search has been performed Text updated, change from the estimation of vitamin
C effect from the Mantel-Haenszel RR to the Peto OR
H I S T O R Y
Protocol first published: Issue 3, 2007
Review first published: Issue 2, 2008
Date Event Description
26 August 2011 New search has been performed Second update, new search, no new trials identified,
conclusions not changed
19 November 2009 New search has been performed New search, no new trials identified, conclusions not
changed
11 November 2008 Amended Contact details updated
6 August 2008 Amended Converted to new review format
15 January 2008 New citation required and conclusions have changed Substantive amendment
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D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
In the previous versions of the review, the Mantel-Haenszel method (M-H) was used to calculate the RR as an estimate of the vitamin C
effect. However, since one of the cells in the 2 × 2 table for the younger tetanus patients was empty, the M-H method gives substantially
conservative estimates, which means much too wide 95% CI. Therefore the Peto-method was used in the 2013 update for calculating
the OR as an approximation of the RR. For the young tetanus patients (1 to 12 yr), the 95% CI limits of the Peto-OR are much closer
to the exact OR limits, and the P-value given by the Peto-method to the young tetanus patients (P = 9.9 x 10−10, Z = 6.0) is close to
the Fisher’s exact test (P = 2.6 x 10−10). This change does not influence the conclusions but makes the presentation in Figure 1 more
appropriate.
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